{"id":49489,"date":"2024-07-23T09:05:41","date_gmt":"2024-07-23T08:05:41","guid":{"rendered":"https:\/\/www.innovationnewsnetwork.com\/?p=49489"},"modified":"2024-07-23T09:05:41","modified_gmt":"2024-07-23T08:05:41","slug":"cepi-funds-valneva-e41-3m-to-advance-chikungunya-vaccine","status":"publish","type":"post","link":"https:\/\/www.innovationnewsnetwork.com\/cepi-funds-valneva-e41-3m-to-advance-chikungunya-vaccine\/49489\/","title":{"rendered":"CEPI funds Valneva \u20ac41.3m to advance chikungunya vaccine development"},"content":{"rendered":"

The Coalition for Epidemic Preparedness Innovations (CEPI) will provide Valneva SE \u20ac41.3m funding to support the development of the world’s first chikungunya vaccine.<\/h2>\n

The vaccine for chikungunya, known as IXCHIQ\u00ae, represents a game-changer in combatting the viral disease.<\/p>\n

The extended partnership between CEPI and Valneva will help improve access to the chikungunya vaccine in low- and middle-income countries (LMICs) and support post-marketing trials and potential label extensions for children, adolescents, and pregnant women.<\/p>\n

Dr Richard Hatchett, Chief Executive Officer of CEPI,\u00a0said, “Millions of people have been affected by chikungunya and, today, over a billion people live in areas where chikungunya outbreaks occur.<\/p>\n

“Access to an affordable chikungunya vaccine in areas where the burden of disease is the greatest is a joint priority for CEPI, Valneva and our European Union partners.<\/p>\n

“These clinical studies and tech transfer to an additional endemic-region manufacturer will accelerate endemic country access, inform future vaccine rollout strategies and alleviate the burden of future chikungunya outbreaks.”<\/p>\n

What is chikungunya?<\/h3>\n

Chikungunya<\/a> is a viral disease transmitted to humans by infected mosquitoes, primarily Aedes aegypti<\/em> and Aedes albopictus<\/em>. It was first identified during an outbreak in Tanzania in 1952.<\/p>\n

The name ‘chikungunya’ derives from a Makonde word meaning ‘to become contorted,’ reflecting the stooped appearance of sufferers due to severe joint pain.<\/p>\n

The virus belongs to the Alphavirus genus of the Togaviridae family. Symptoms typically appear 4-8 days after being bitten by an infected mosquito and include sudden high fever, joint pain, muscle pain, headache, nausea, fatigue, and rash.<\/p>\n

Joint pain is often debilitating and can last for weeks or months, but fatalities are rare.<\/p>\n

There’s no specific antiviral treatment for chikungunya; management focuses on relieving symptoms with rest, fluids, and pain relievers like acetaminophen or ibuprofen.<\/p>\n

Preventive measures are crucial, including using insect repellent, wearing long sleeves and pants, and eliminating standing water where mosquitoes breed.<\/p>\n

Although chikungunya rarely leads to long-term health issues, its acute symptoms can be severe and significantly impact the quality of life.<\/p>\n

With global travel, the virus has spread to many regions, making awareness and prevention measures, such as vaccines<\/a>, critical.<\/p>\n

CEPI funding for chikungunya vaccine development<\/h3>\n

CEPI will provide Valneva with up to $41.3m over the next five years, supported by the EU\u2019s Horizon Europe programme<\/a>.<\/p>\n

This funding aims to generate additional data to potentially extend IXCHIQ\u00ae vaccine labels in chikungunya-endemic countries and among vulnerable populations.<\/p>\n

Planned trials and target populations<\/h3>\n

Starting in 2025, several thousand participants will join the trials, focusing on children aged 1-11 and pregnant women in areas at risk of chikungunya.<\/p>\n

Brazil, currently facing a significant outbreak with over 340,000 cases reported this year, will host some of these trials.<\/p>\n

Strengthening existing partnerships<\/h3>\n

This expanded partnership builds on an earlier agreement that provided Valneva $24.6m in CEPI-EU funding to develop, manufacture, and market the vaccine in certain LMICs.<\/p>\n

Valneva, in collaboration with Brazil\u2019s Instituto Butantan (IB), conducted an adolescent clinical trial in Brazil in 2021.<\/p>\n

The Brazilian Health Regulatory Agency (ANVISA) is currently reviewing the marketing authorization application for IXCHIQ\u00ae, with potential approval expected in 2024.<\/p>\n

IB is committed to developing and producing the chikungunya vaccine in Brazil at an affordable price for distribution in Latin America and selected LMICs.<\/p>\n

CEPI-EU funding will also support the technology transfer of the vaccine drug product to an additional manufacturer, accelerating access to IXCHIQ\u00ae in Asian LMICs vulnerable to chikungunya outbreaks.<\/p>\n","protected":false},"excerpt":{"rendered":"

CEPI will provide Valneva SE \u20ac41.3m funding to support the development of the world’s first chikungunya vaccine.<\/p>\n","protected":false},"author":15,"featured_media":49490,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_monsterinsights_skip_tracking":false,"_monsterinsights_sitenote_active":false,"_monsterinsights_sitenote_note":"","_monsterinsights_sitenote_category":0,"footnotes":""},"categories":[10551],"tags":[24564,24360],"acf":[],"yoast_head":"\nCEPI funds Valneva \u20ac41.3m to advance chikungunya vaccine<\/title>\n<meta name=\"description\" content=\"CEPI will provide Valneva SE \u20ac41.3m funding to support the development of the world's first chikungunya vaccine.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.innovationnewsnetwork.com\/cepi-funds-valneva-e41-3m-to-advance-chikungunya-vaccine\/49489\/\" \/>\n<meta property=\"og:locale\" content=\"en_GB\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"CEPI funds Valneva \u20ac41.3m to advance chikungunya vaccine development\" \/>\n<meta property=\"og:description\" content=\"CEPI will provide Valneva SE \u20ac41.3m funding to support the development of the world's first chikungunya vaccine.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.innovationnewsnetwork.com\/cepi-funds-valneva-e41-3m-to-advance-chikungunya-vaccine\/49489\/\" \/>\n<meta property=\"og:site_name\" content=\"Innovation News Network\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/InnoNewsNetwork\" \/>\n<meta property=\"article:published_time\" content=\"2024-07-23T08:05:41+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.innovationnewsnetwork.com\/wp-content\/uploads\/2024\/07\/shutterstock_2477803627.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1000\" \/>\n\t<meta property=\"og:image:height\" content=\"607\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Jack Thomas\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@InnoNewsNetwork\" \/>\n<meta name=\"twitter:site\" content=\"@InnoNewsNetwork\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Jack Thomas\" \/>\n\t<meta name=\"twitter:label2\" content=\"Estimated reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/www.innovationnewsnetwork.com\/cepi-funds-valneva-e41-3m-to-advance-chikungunya-vaccine\/49489\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/www.innovationnewsnetwork.com\/cepi-funds-valneva-e41-3m-to-advance-chikungunya-vaccine\/49489\/\"},\"author\":{\"name\":\"Jack Thomas\",\"@id\":\"https:\/\/www.innovationnewsnetwork.com\/#\/schema\/person\/e34bceac54cf8934b0df3f4c8c2a649d\"},\"headline\":\"CEPI funds Valneva \u20ac41.3m to advance chikungunya vaccine development\",\"datePublished\":\"2024-07-23T08:05:41+00:00\",\"dateModified\":\"2024-07-23T08:05:41+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/www.innovationnewsnetwork.com\/cepi-funds-valneva-e41-3m-to-advance-chikungunya-vaccine\/49489\/\"},\"wordCount\":568,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\/\/www.innovationnewsnetwork.com\/#organization\"},\"image\":{\"@id\":\"https:\/\/www.innovationnewsnetwork.com\/cepi-funds-valneva-e41-3m-to-advance-chikungunya-vaccine\/49489\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/www.innovationnewsnetwork.com\/wp-content\/uploads\/2024\/07\/shutterstock_2477803627.jpg\",\"keywords\":[\"Horizon Europe\",\"Infection Control\"],\"articleSection\":[\"Health\"],\"inLanguage\":\"en-GB\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/www.innovationnewsnetwork.com\/cepi-funds-valneva-e41-3m-to-advance-chikungunya-vaccine\/49489\/#respond\"]}],\"copyrightYear\":\"2024\",\"copyrightHolder\":{\"@id\":\"https:\/\/www.innovationnewsnetwork.com\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.innovationnewsnetwork.com\/cepi-funds-valneva-e41-3m-to-advance-chikungunya-vaccine\/49489\/\",\"url\":\"https:\/\/www.innovationnewsnetwork.com\/cepi-funds-valneva-e41-3m-to-advance-chikungunya-vaccine\/49489\/\",\"name\":\"CEPI funds Valneva \u20ac41.3m to advance chikungunya vaccine\",\"isPartOf\":{\"@id\":\"https:\/\/www.innovationnewsnetwork.com\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/www.innovationnewsnetwork.com\/cepi-funds-valneva-e41-3m-to-advance-chikungunya-vaccine\/49489\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/www.innovationnewsnetwork.com\/cepi-funds-valneva-e41-3m-to-advance-chikungunya-vaccine\/49489\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/www.innovationnewsnetwork.com\/wp-content\/uploads\/2024\/07\/shutterstock_2477803627.jpg\",\"datePublished\":\"2024-07-23T08:05:41+00:00\",\"dateModified\":\"2024-07-23T08:05:41+00:00\",\"description\":\"CEPI will provide Valneva SE \u20ac41.3m funding to support the development of the world's first chikungunya vaccine.\",\"breadcrumb\":{\"@id\":\"https:\/\/www.innovationnewsnetwork.com\/cepi-funds-valneva-e41-3m-to-advance-chikungunya-vaccine\/49489\/#breadcrumb\"},\"inLanguage\":\"en-GB\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.innovationnewsnetwork.com\/cepi-funds-valneva-e41-3m-to-advance-chikungunya-vaccine\/49489\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-GB\",\"@id\":\"https:\/\/www.innovationnewsnetwork.com\/cepi-funds-valneva-e41-3m-to-advance-chikungunya-vaccine\/49489\/#primaryimage\",\"url\":\"https:\/\/www.innovationnewsnetwork.com\/wp-content\/uploads\/2024\/07\/shutterstock_2477803627.jpg\",\"contentUrl\":\"https:\/\/www.innovationnewsnetwork.com\/wp-content\/uploads\/2024\/07\/shutterstock_2477803627.jpg\",\"width\":1000,\"height\":607,\"caption\":\"\u00a9shutterstock\/Kitsawet Saethao\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/www.innovationnewsnetwork.com\/cepi-funds-valneva-e41-3m-to-advance-chikungunya-vaccine\/49489\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/www.innovationnewsnetwork.com\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"CEPI funds Valneva \u20ac41.3m to advance chikungunya vaccine development\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.innovationnewsnetwork.com\/#website\",\"url\":\"https:\/\/www.innovationnewsnetwork.com\/\",\"name\":\"Innovation News Network\",\"description\":\"Science, Research & Innovation News\",\"publisher\":{\"@id\":\"https:\/\/www.innovationnewsnetwork.com\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.innovationnewsnetwork.com\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"en-GB\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/www.innovationnewsnetwork.com\/#organization\",\"name\":\"Innovation News Network\",\"url\":\"https:\/\/www.innovationnewsnetwork.com\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-GB\",\"@id\":\"https:\/\/www.innovationnewsnetwork.com\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/www.innovationnewsnetwork.com\/wp-content\/uploads\/2022\/01\/inn-logo-yoast-seo-organisation-1920-1080-001.jpg\",\"contentUrl\":\"https:\/\/www.innovationnewsnetwork.com\/wp-content\/uploads\/2022\/01\/inn-logo-yoast-seo-organisation-1920-1080-001.jpg\",\"width\":1920,\"height\":1080,\"caption\":\"Innovation News Network\"},\"image\":{\"@id\":\"https:\/\/www.innovationnewsnetwork.com\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.facebook.com\/InnoNewsNetwork\",\"https:\/\/x.com\/InnoNewsNetwork\",\"https:\/\/www.linkedin.com\/company\/innovation-news-network\/\"]},{\"@type\":\"Person\",\"@id\":\"https:\/\/www.innovationnewsnetwork.com\/#\/schema\/person\/e34bceac54cf8934b0df3f4c8c2a649d\",\"name\":\"Jack Thomas\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-GB\",\"@id\":\"https:\/\/www.innovationnewsnetwork.com\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/b61be388a9781729729469d3dcf95087?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/b61be388a9781729729469d3dcf95087?s=96&d=mm&r=g\",\"caption\":\"Jack Thomas\"},\"sameAs\":[\"https:\/\/www.innovationnewsnetwork.com\"],\"url\":\"https:\/\/www.innovationnewsnetwork.com\/author\/jackthomas\/\"}]}<\/script>\n","yoast_head_json":{"title":"CEPI funds Valneva \u20ac41.3m to advance chikungunya vaccine","description":"CEPI will provide Valneva SE \u20ac41.3m funding to support the development of the world's first chikungunya vaccine.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.innovationnewsnetwork.com\/cepi-funds-valneva-e41-3m-to-advance-chikungunya-vaccine\/49489\/","og_locale":"en_GB","og_type":"article","og_title":"CEPI funds Valneva \u20ac41.3m to advance chikungunya vaccine development","og_description":"CEPI will provide Valneva SE \u20ac41.3m funding to support the development of the world's first chikungunya vaccine.","og_url":"https:\/\/www.innovationnewsnetwork.com\/cepi-funds-valneva-e41-3m-to-advance-chikungunya-vaccine\/49489\/","og_site_name":"Innovation News Network","article_publisher":"https:\/\/www.facebook.com\/InnoNewsNetwork","article_published_time":"2024-07-23T08:05:41+00:00","og_image":[{"width":1000,"height":607,"url":"https:\/\/www.innovationnewsnetwork.com\/wp-content\/uploads\/2024\/07\/shutterstock_2477803627.jpg","type":"image\/jpeg"}],"author":"Jack Thomas","twitter_card":"summary_large_image","twitter_creator":"@InnoNewsNetwork","twitter_site":"@InnoNewsNetwork","twitter_misc":{"Written by":"Jack Thomas","Estimated reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.innovationnewsnetwork.com\/cepi-funds-valneva-e41-3m-to-advance-chikungunya-vaccine\/49489\/#article","isPartOf":{"@id":"https:\/\/www.innovationnewsnetwork.com\/cepi-funds-valneva-e41-3m-to-advance-chikungunya-vaccine\/49489\/"},"author":{"name":"Jack Thomas","@id":"https:\/\/www.innovationnewsnetwork.com\/#\/schema\/person\/e34bceac54cf8934b0df3f4c8c2a649d"},"headline":"CEPI funds Valneva \u20ac41.3m to advance chikungunya vaccine development","datePublished":"2024-07-23T08:05:41+00:00","dateModified":"2024-07-23T08:05:41+00:00","mainEntityOfPage":{"@id":"https:\/\/www.innovationnewsnetwork.com\/cepi-funds-valneva-e41-3m-to-advance-chikungunya-vaccine\/49489\/"},"wordCount":568,"commentCount":0,"publisher":{"@id":"https:\/\/www.innovationnewsnetwork.com\/#organization"},"image":{"@id":"https:\/\/www.innovationnewsnetwork.com\/cepi-funds-valneva-e41-3m-to-advance-chikungunya-vaccine\/49489\/#primaryimage"},"thumbnailUrl":"https:\/\/www.innovationnewsnetwork.com\/wp-content\/uploads\/2024\/07\/shutterstock_2477803627.jpg","keywords":["Horizon Europe","Infection Control"],"articleSection":["Health"],"inLanguage":"en-GB","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/www.innovationnewsnetwork.com\/cepi-funds-valneva-e41-3m-to-advance-chikungunya-vaccine\/49489\/#respond"]}],"copyrightYear":"2024","copyrightHolder":{"@id":"https:\/\/www.innovationnewsnetwork.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/www.innovationnewsnetwork.com\/cepi-funds-valneva-e41-3m-to-advance-chikungunya-vaccine\/49489\/","url":"https:\/\/www.innovationnewsnetwork.com\/cepi-funds-valneva-e41-3m-to-advance-chikungunya-vaccine\/49489\/","name":"CEPI funds Valneva \u20ac41.3m to advance chikungunya vaccine","isPartOf":{"@id":"https:\/\/www.innovationnewsnetwork.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.innovationnewsnetwork.com\/cepi-funds-valneva-e41-3m-to-advance-chikungunya-vaccine\/49489\/#primaryimage"},"image":{"@id":"https:\/\/www.innovationnewsnetwork.com\/cepi-funds-valneva-e41-3m-to-advance-chikungunya-vaccine\/49489\/#primaryimage"},"thumbnailUrl":"https:\/\/www.innovationnewsnetwork.com\/wp-content\/uploads\/2024\/07\/shutterstock_2477803627.jpg","datePublished":"2024-07-23T08:05:41+00:00","dateModified":"2024-07-23T08:05:41+00:00","description":"CEPI will provide Valneva SE \u20ac41.3m funding to support the development of the world's first chikungunya vaccine.","breadcrumb":{"@id":"https:\/\/www.innovationnewsnetwork.com\/cepi-funds-valneva-e41-3m-to-advance-chikungunya-vaccine\/49489\/#breadcrumb"},"inLanguage":"en-GB","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.innovationnewsnetwork.com\/cepi-funds-valneva-e41-3m-to-advance-chikungunya-vaccine\/49489\/"]}]},{"@type":"ImageObject","inLanguage":"en-GB","@id":"https:\/\/www.innovationnewsnetwork.com\/cepi-funds-valneva-e41-3m-to-advance-chikungunya-vaccine\/49489\/#primaryimage","url":"https:\/\/www.innovationnewsnetwork.com\/wp-content\/uploads\/2024\/07\/shutterstock_2477803627.jpg","contentUrl":"https:\/\/www.innovationnewsnetwork.com\/wp-content\/uploads\/2024\/07\/shutterstock_2477803627.jpg","width":1000,"height":607,"caption":"\u00a9shutterstock\/Kitsawet Saethao"},{"@type":"BreadcrumbList","@id":"https:\/\/www.innovationnewsnetwork.com\/cepi-funds-valneva-e41-3m-to-advance-chikungunya-vaccine\/49489\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.innovationnewsnetwork.com\/"},{"@type":"ListItem","position":2,"name":"CEPI funds Valneva \u20ac41.3m to advance chikungunya vaccine development"}]},{"@type":"WebSite","@id":"https:\/\/www.innovationnewsnetwork.com\/#website","url":"https:\/\/www.innovationnewsnetwork.com\/","name":"Innovation News Network","description":"Science, Research & Innovation News","publisher":{"@id":"https:\/\/www.innovationnewsnetwork.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.innovationnewsnetwork.com\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"en-GB"},{"@type":"Organization","@id":"https:\/\/www.innovationnewsnetwork.com\/#organization","name":"Innovation News Network","url":"https:\/\/www.innovationnewsnetwork.com\/","logo":{"@type":"ImageObject","inLanguage":"en-GB","@id":"https:\/\/www.innovationnewsnetwork.com\/#\/schema\/logo\/image\/","url":"https:\/\/www.innovationnewsnetwork.com\/wp-content\/uploads\/2022\/01\/inn-logo-yoast-seo-organisation-1920-1080-001.jpg","contentUrl":"https:\/\/www.innovationnewsnetwork.com\/wp-content\/uploads\/2022\/01\/inn-logo-yoast-seo-organisation-1920-1080-001.jpg","width":1920,"height":1080,"caption":"Innovation News Network"},"image":{"@id":"https:\/\/www.innovationnewsnetwork.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/InnoNewsNetwork","https:\/\/x.com\/InnoNewsNetwork","https:\/\/www.linkedin.com\/company\/innovation-news-network\/"]},{"@type":"Person","@id":"https:\/\/www.innovationnewsnetwork.com\/#\/schema\/person\/e34bceac54cf8934b0df3f4c8c2a649d","name":"Jack Thomas","image":{"@type":"ImageObject","inLanguage":"en-GB","@id":"https:\/\/www.innovationnewsnetwork.com\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/b61be388a9781729729469d3dcf95087?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/b61be388a9781729729469d3dcf95087?s=96&d=mm&r=g","caption":"Jack Thomas"},"sameAs":["https:\/\/www.innovationnewsnetwork.com"],"url":"https:\/\/www.innovationnewsnetwork.com\/author\/jackthomas\/"}]}},"publishpress_future_action":{"enabled":false,"date":"2025-03-05 18:31:39","action":"change-status","newStatus":"draft","terms":[],"taxonomy":"category"},"_links":{"self":[{"href":"https:\/\/www.innovationnewsnetwork.com\/wp-json\/wp\/v2\/posts\/49489"}],"collection":[{"href":"https:\/\/www.innovationnewsnetwork.com\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.innovationnewsnetwork.com\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.innovationnewsnetwork.com\/wp-json\/wp\/v2\/users\/15"}],"replies":[{"embeddable":true,"href":"https:\/\/www.innovationnewsnetwork.com\/wp-json\/wp\/v2\/comments?post=49489"}],"version-history":[{"count":2,"href":"https:\/\/www.innovationnewsnetwork.com\/wp-json\/wp\/v2\/posts\/49489\/revisions"}],"predecessor-version":[{"id":49492,"href":"https:\/\/www.innovationnewsnetwork.com\/wp-json\/wp\/v2\/posts\/49489\/revisions\/49492"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.innovationnewsnetwork.com\/wp-json\/wp\/v2\/media\/49490"}],"wp:attachment":[{"href":"https:\/\/www.innovationnewsnetwork.com\/wp-json\/wp\/v2\/media?parent=49489"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.innovationnewsnetwork.com\/wp-json\/wp\/v2\/categories?post=49489"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.innovationnewsnetwork.com\/wp-json\/wp\/v2\/tags?post=49489"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}